Reboxetine Enhances the Olanzapine-induced Antipsychotic-like Effect, Cortical Dopamine Outflow and NMDA Receptor-Mediated Transmission.
Résumé
Preclinical data have shown that addition of the selective norepinephrine transporter (NET) inhibitor reboxetine increases the antipsychotic-like effect of the D2/3 antagonist raclopride and, in parallel, enhances cortical dopamine output. Subsequent clinical results suggested that adding reboxetine to stable treatments with various antipsychotic drugs (APDs) may improve positive, negative and depressive symptoms in schizophrenia. Here we investigated in rats the effects of adding reboxetine to the second generation APD olanzapine on: i) antipsychotic efficacy, using the conditioned avoidance response (CAR) test, ii) extrapyramidal side effect (EPS) liability, using a catalepsy test, iii) dopamine efflux in the medial prefrontal cortex and the nucleus accumbens, using in vivo microdialysis in freely moving animals, and iv) cortical NMDA receptor-mediated transmission, using intracellular electrophysiological recording in vitro. Reboxetine (6 mg/kg) enhanced the suppression of CAR induced by a suboptimal dose (1.25 mg/kg), but not an optimal (2.5 mg/kg) dose of olanzapine without any concomitant catalepsy. Addition of reboxetine to the low dose of olanzapine also markedly increased cortical dopamine outflow and facilitated prefrontal NMDA receptor-mediated transmission. Our data propose that adjunctive treatment with a NET inhibitor may enhance the therapeutic effect of low dose olanzapine in schizophrenia without increasing EPS liability and add an antidepressant action, thus in principle allowing for a dose reduction of olanzapine with a concomitant reduction of dose-related side effects, such as EPS and weight gain.
Origine : Fichiers produits par l'(les) auteur(s)
Loading...